April 16, 2020 Nimble & Svar Life Science Announce Collaboration to Discover, Develop and Commercialize Diagnostic Tests based on Nimble’s Novel Biomarker Discovery Engine MADISON, WI, USA and Malmö, SE — Nimble Therapeutics and Svar Life Science today announced a collaboration to discover, develop,
April 8, 2020 Precision NanoSystems Appoints Dr. Andrew Geall as Chief Scientific Officer Vancouver BC, April 8, 2020 Precision NanoSystems (PNI), a global leader in enabling transformative nanomedicines today announced the appointment of
April 1, 2020 Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC) Funded by the Bill and Melinda Gates Foundation, CoVIC Seeks to Find Therapeutic Candidates for COVID-19 in Just Weeks Salt
March 27, 2020 Dynex® Technologies Assisting in the Fight Against COVID-19 Dynex’s portfolio of open, automated microplate instruments, with a global distribution network and footprint, demonstrates ability to support COVID-19 testing
March 25, 2020 Precision NanoSystems announces partnership with Fujifilm for the development and GMP manufacturing of nanoparticle based therapeutics Vancouver BC, March 23, 2020 Precision Nanosystems, Inc. (PNI), a global leader in enabling transformative nanomedicines announced today that the
March 23, 2020 Immediate COVID-19 Vaccine & Therapeutic Fill/Finish Production Availability Announced by Argonaut Manufacturing Services Advanced Facility Readies to Combat COVID-19 (Carlsbad, CA) March 23, 2020 – Argonaut Manufacturing Services announced today it has immediate
March 16, 2020 Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control New reference material aims to facilitate and expedite global efforts to detect the novel coronavirus AUSTIN, Texas–(BUSINESS WIRE)– Asuragen, Inc.
February 27, 2020 RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay Seattle, WA, February 27, 2020 – RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling
February 26, 2020 Active Motif clones, sequences and expresses the first full human antibody derived from patients infected with the 2019 Coronavirus COVID-19 Active Motif Shanghai (a subsidiary of Active Motif, Inc.), in collaboration with Fudan University and its affiliated Public Health Clinical
February 22, 2020 FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome The U.S. Food and Drug Administration today authorized marketing of the first test to detect a genetic condition known as